BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice
about
7,8-Dihydroxyflavone, a small molecule TrkB agonist, improves spatial memory and increases thin spine density in a mouse model of Alzheimer disease-like neuronal lossMood disorders in Huntington's disease: from behavior to cellular and molecular mechanismsMultiple Aspects of Gene Dysregulation in Huntington's DiseaseNeural and mesenchymal stem cells in animal models of Huntington's disease: past experiences and future challengesDeveloping stem cell therapies for juvenile and adult-onset Huntington's diseaseLong non-coding RNA-dependent transcriptional regulation in neuronal development and diseaseMouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.Reinstating aberrant mTORC1 activity in Huntington's disease mice improves disease phenotypes.Amitriptyline improves motor function via enhanced neurotrophin signaling and mitochondrial functions in the murine N171-82Q Huntington disease model.Induction of DARPP-32 by brain-derived neurotrophic factor in striatal neurons in vitro is modified by histone deacetylase inhibitors and Nab2The CB1 cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathwayGenetic deletion of the Histone Deacetylase 6 exacerbates selected behavioral deficits in the R6/1 mouse model for Huntington's disease.BDNF-TrkB signaling in striatopallidal neurons controls inhibition of locomotor behavior.Use of Genetically Altered Stem Cells for the Treatment of Huntington's Disease.Neurotoxicity of human immunodeficiency virus-1: viral proteins and axonal transportBDNF signaling and survival of striatal neurons.Dendritic BDNF synthesis is required for late-phase spine maturation and recovery of cortical responses following sensory deprivation.Preclinical and clinical investigations of mood stabilizers for Huntington's disease: what have we learned?Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's diseaseDifferential loss of thalamostriatal and corticostriatal input to striatal projection neuron types prior to overt motor symptoms in the Q140 knock-in mouse model of Huntington's disease.Small and Long Regulatory RNAs in the Immune System and Immune DiseasesIntrastriatal transplantation of neurotrophic factor-secreting human mesenchymal stem cells improves motor function and extends survival in R6/2 transgenic mouse model for Huntington's disease.Therapeutic advances in Huntington's Disease.TrkB receptor controls striatal formation by regulating the number of newborn striatal neurons.New insight in expression, transport, and secretion of brain-derived neurotrophic factor: Implications in brain-related diseases.From discovery to function: the expanding roles of long noncoding RNAs in physiology and disease.Transcription, epigenetics and ameliorative strategies in Huntington's Disease: a genome-wide perspectiveExpansion of the dentate mossy fiber-CA3 projection in the brain-derived neurotrophic factor-enriched mouse hippocampus.A monoclonal antibody TrkB receptor agonist as a potential therapeutic for Huntington's disease.Postnatal administration of allopregnanolone modifies glutamate release but not BDNF content in striatum samples of rats prenatally exposed to ethanolHuntington's Disease and Striatal Signaling.Conditional BDNF release under pathological conditions improves Huntington's disease pathology by delaying neuronal dysfunction.HD iPSC-derived neural progenitors accumulate in culture and are susceptible to BDNF withdrawal due to glutamate toxicity.Disease Modifying Potential of Glatiramer Acetate in Huntington's DiseaseCognitive training modifies disease symptoms in a mouse model of Huntington's diseaseThe group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease miceBDNF may play a differential role in the protective effect of the mGluR2/3 agonist LY379268 on striatal projection neurons in R6/2 Huntington's disease mice.Brain-derived neurotrophic factor and its clinical implications.Impaired TrkB Signaling Underlies Reduced BDNF-Mediated Trophic Support of Striatal Neurons in the R6/2 Mouse Model of Huntington's Disease.Selective reduction of striatal mature BDNF without induction of proBDNF in the zQ175 mouse model of Huntington's disease
P2860
Q21090643-E534BA37-4E0C-4EBC-A164-0D60A18A099FQ21131050-FC263D59-3546-4B7C-8AA7-E237C07D6C47Q24605880-BC53C838-09D9-4769-B4C7-7BC9DB3D47DFQ26775932-5A93EA43-3AC2-42A7-BCE6-AC16605E60D1Q26799722-298A1F31-BDA2-417A-AD83-4185CF39AE69Q26999388-852B4AEC-9B42-4813-BB33-15DFF7A0DD70Q27005950-5514525D-3155-4FF8-B7A6-E468F0253DA6Q27306293-437FD399-2BD2-4494-A762-66DB4C5F03E1Q27314860-5E27D66C-CAC0-4CD8-A0BD-AB8C7C517A3EQ28534553-2DCB9ADC-614B-4162-83DC-02D232C3D4BBQ29306901-4DCECA91-372E-4093-A393-26268F4EA2C0Q30401432-095CE1F2-D40D-4D94-9221-B453677C53AEQ30573241-109AC0D7-6B58-49CB-A41A-849F11B62613Q33788929-DFB14C1A-46EF-4169-8687-D762D1D75129Q33870898-E43EEFBB-6E6B-4C9D-BF7E-849BE5C44A4FQ34102098-F851BB82-6E4E-49AE-8EFA-E44466E9AD5CQ34267206-A5C3A6CA-8813-4100-8799-FFA7F1F19DB8Q34284039-1719CC5F-B6CC-4F2E-9286-6C49E6DF61B1Q34330172-AEC3AD68-BFB0-4B87-A138-A0A636BBC334Q34341619-983A2061-8939-4A5C-A0A4-E2CDC515E8CFQ34368789-E71FCE22-D232-4C47-9311-C85F5FDF5F45Q34406937-2CBEFED4-961E-472D-9562-6C3CDFD2AF6AQ34487604-2A0D2E10-A7E0-434B-AB53-9CD870331F6BQ34533677-A8F79188-B20E-42E3-A509-B36206866385Q34567939-68A0AE53-1DDF-4D7F-8F7B-16D46856FC3CQ35024083-4746497E-308C-4777-831E-342BC483B44EQ35024695-0BA49D04-B136-4554-A08C-60D86B07D9D1Q35073511-46D3BF40-2613-4388-92FE-ED6D5C30ED64Q35087700-4B67C9D1-0257-4B0A-9697-2870A0AD038DQ35156118-1C61B363-9DD9-4538-AE56-50D6ACB7CE09Q35286098-B0F99426-4E6B-4672-865E-F9A1CA3D2366Q35487248-78F5954D-F250-45AF-9972-4CB0297A3C58Q35585297-3A3BC06A-9A35-4D66-9E6F-33ADC54F943AQ35782283-BBB48B76-5DA1-4B31-91CD-30051FE15D40Q36013200-2CF3CF8B-8622-4C4F-A9A0-17F961D3EEADQ36037085-61A2B2B3-D647-4BDB-8063-C59DBF90A4C7Q36191786-A18709F2-9605-47E3-8413-707C99293F97Q36418981-09FC7621-FB82-4CC8-AE3F-668CEE9876B2Q36665616-2FB17DA4-96E4-4137-8F95-629F6527663DQ36761088-07E3AD51-6420-46B5-B95B-9136C137D98F
P2860
BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
BDNF overexpression in the for ...... ease phenotypes in YAC128 mice
@ast
BDNF overexpression in the for ...... ease phenotypes in YAC128 mice
@en
BDNF overexpression in the for ...... ease phenotypes in YAC128 mice
@nl
type
label
BDNF overexpression in the for ...... ease phenotypes in YAC128 mice
@ast
BDNF overexpression in the for ...... ease phenotypes in YAC128 mice
@en
BDNF overexpression in the for ...... ease phenotypes in YAC128 mice
@nl
prefLabel
BDNF overexpression in the for ...... ease phenotypes in YAC128 mice
@ast
BDNF overexpression in the for ...... ease phenotypes in YAC128 mice
@en
BDNF overexpression in the for ...... ease phenotypes in YAC128 mice
@nl
P2860
P1476
BDNF overexpression in the for ...... ease phenotypes in YAC128 mice
@en
P2093
P2860
P304
14708-14718
P356
10.1523/JNEUROSCI.1637-10.2010
P407
P577
2010-11-01T00:00:00Z